the aid library

LIST OPTIONS

Filter

5257

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (590)

View PDF (971)

Ensuring health security in the African region - Emergency preparedness and response flagship programmes

World Health Organization WHO, Regional Office of Africa (2022) C_WHO

The World Health Organization Regional Office for Africa (WHO AFRO), in accordance with recommendations from various WHO committees, has developed three flagship programmes to support Member States in the African region to prepare for, detect and respond to public health emergencies. They are the re... more

Download (496)

View PDF (621)

The Global Status Report on Preventing Violence Against Children 2020

UNICEF WHO (2020) C_WHO

As this report shows, reports of child abuse and of children witnessing violence between their parents and caregivers have increased. Ending violence against children is increasingly within our reach. D

Download (422)

View PDF (408)

Rapport de situation mondial sur les services WASH dans les établissements de santé: les impératifs premiers

Organisation Mondiale de la Sante, Unicef WHO (2021) C_WHO

Ce rapport identifie les principales lacunes mondiales dans les services WASH : un tiers des établissements de santé ne dispose pas des installations de lavage des mains nécessaires sur les lieux de soins ; un établissement sur quatre n’a pas de services de base pour l’approvisionnement en e... more

Download (361)

View PDF (612)

mhGAP Programme d’action Combler les lacunes en santé mentale

World Health Organization WHO (2013) C_WHO

Élargir l’accès aux soins pour lutter contre les troubles mentaux, neurologiques et liés à l’utilisation de substances psychoactives

Download (791)

View PDF (671)

Manuel pour le renforcement des compétences : le conseil pour la prise en charge de la santé maternelle et néonatale.

World Health Organization WHO WHO (2013) C_WHO

Updated 2013

External Link

Cartographie des Systemes d’Approvisionnement et de Distribution des Medicaments et autres Produits de Santé au Burkina Faso

MinistÈre de la Santé Sécrétariat General, Direction Generale de la Pharmacie, du Médicament et des Laboratoires, Burkina Faso WHO (OMS) (2010) C_WHO

L’accessibilité géographique et financière constante des médicaments essentiels de qualité, sûrs et efficaces aux populations est un objectif majeur des politiques pharmaceutiques nationales. Pour atteindre cet objectif, le Ministère de la Santé du Burkina Faso a mis en place un systèm... more

Download (323)

View PDF (449)

Rapport annuel 2023

World Health Organization WHO (2024) C_WHO

En 2023, la nouvelle stratégie de Coopération de l’OMS avec le Niger 2023-2027 a été lancée, assortie d’un plan d’investissement. En outre, l’OMS a soutenu plusieurs initiatives majeures du pays, comme le lancement effectif de la Stratégie nationale de la Couverture Sanitaire Universel... more

Download (94)

View PDF (100)

Lignes directrices de l'OMS sur le paludisme

World Health Organisation (WHO) (2024) C_WHO

Les Lignes directrices de l'OMS sur le paludisme rassemblent les recommandations les plus récentes de l'Organisation pour le paludisme dans une plateforme en ligne facile à utiliser et à naviguer. Les Lignes directrices de l'OMS sur le paludisme remplacent 2 publications précédentes de l'OMS... more

Download (25453)

View PDF (5078)

Manual of diagnostic ultrasound. Vol. 2 – 2nd ed.

Elisabetta Buscarini, Harald Lutz and Paoletta Mirk WHO (2013)

Download (1860)

View PDF (2319)

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers

World Health Organization WHO (2021) C_WHO

2nd. edition The new edition has been developed to make widely available to programme managers, health care workers in endemic settings, academic researchers, and other key partners, a concise source of information on strategies for MMDP for LF. It is a product of efforts to elaborate and concepts ... more

Download (893)

View PDF (2341)

Priority assistive products list.Список приоритетных вспомогательных устройств (СВУ)

World Health Organization WHO (2016) C_WHO

Download (455)

View PDF (345)

Nigeria Country Office 2021 Annual Report

World Health Organization WHO (2022) C_WHO

This annual report highlights the work of the WHO from January to June 2021 ( December 2021). The activities featured herein are by no means exhausted but implemented with technical and financial support through WHO in Nigeria; facilitated by its presence at all levels of governance (national, state... more

Download (375)

View PDF (391)

Innovative delivery systems for paediatric medicines

World Health Organization WHO; Unitaid (2020) C_WHO

Technology landscape

Download (1381)

View PDF (1965)

A New Way to Talk about the Social Determinats of Health

Robert Wood Johnson Foundation (2014) C2

Download (332)

View PDF (411)

SARS-CoV-2 antigen-detecting rapid diagnostic tests: An implementation guide

World Health Organization WHO (2021) C_WHO

This guide provides an overview of the major elements that must be considered before, during and after the implementation of antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2. This guide is complementary to policy guidance issued by the World Health Organization (WHO). The guide may ... more

External Link

Accountability for women’s and children’s health

Flavia Bustreo, Marie-Paule Kieny, Lale Say et al. World Health Organization WHO (2015) C_WHO

Progress Report

Download (434)

View PDF (546)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Download (320)

View PDF (444)

Integration of HIV testing and linkage in family planning and contraception services: implementation brief

World Health Organisation (WHO) (2021) C_WHO

This implementation brief addresses integration of HIV testing services into family planning (FP) services. It is intended as a practical resource for national health programmes seeking to introduce or scale up HIV testing and linkage to HIV prevention, sexually transmitted infection, and antiretrov... more

External Link

World Report on Ageing and Health

John Beard, Alana Officer, Andrew Cassels et al. World Health Organization WHO (2015) C_WHO

Comprehensive public health action on population ageing is urgently needed. This will require fundamental shifts, not just in the things we do, but in how we think about ageing itself. The World report on ageing and health outlines a framework for action to foster Healthy Ageing built around the new... more